GlassScriptPhysician profile
Scott A Macleod
NPI 1841359700
$8,904.07
in general payments reported to CMS, 2019-2025
32 companies · $2,526 in 2025
The $2,526 reported for 2025 was more than what 97% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $326 · 2021: $181 · 2022: $542 · 2023: $1,329 · 2024: $3,179 · 2025: $2,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,709 · Education: $325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,708.91 |
| Education | $324.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,574.90 | 2019-2025 | |
| Janssen Biotech, INC. | $998.55 | 2020-2025 | Tremfya |
| Leo Pharma INC. | $664.24 | 2022-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $578.86 | 2019-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $470.11 | 2023-2024 | Vtama |
| Genzyme Corporation | $463.10 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $336.22 | 2020-2025 | Winlevi, Absorica Ld, Ilumya |
| Lilly USA, LLC | $327.58 | 2023-2025 | Ebglyss, Taltz, Olumiant |
| Amgen INC. | $281.00 | 2019-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $258.72 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $186.45 | 2023-2025 | Sotyktu |
| Celgene Corporation | $164.57 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.71 | 2023-2024 | Spevigo |
| Pfizer INC. | $144.08 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $143.88 | 2019-2025 | Dupixent, Libtayo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $139.74 | 2024-2025 | Bimzelx |
| Incyte Corporation | $120.53 | 2024-2025 | Opzelura |
| Janssen Scientific Affairs, LLC | $114.87 | 2024 | Tremfya |
| Organon LLC | $96.09 | 2025 | Vtama |
| Vyne Pharmaceuticals INC. | $94.10 | 2020-2021 | |
| Arcutis Biotherapeutics, INC. | $90.16 | 2024-2025 | Zoryve |
| Regeneron Pharmaceuticals, INC. | $87.10 | 2024-2025 | Dupixent |
| Almirall LLC | $66.47 | 2019-2025 | Klisyri |
| Hill Dermaceuticals, INC. | $61.99 | 2023 | Tolak |
| Dermira, INC. | $48.25 | 2019-2020 | |
| Strata Skin Sciences, INC. | $47.51 | 2022-2023 | Xtrac |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $46.25 | 2024 | Duobrii, Siliq, Cabtreo |
| Mayne Pharma Commercial LLC | $42.87 | 2019-2020 | |
| Sandoz INC. | $39.40 | 2023-2024 | Hyrimoz |
| Kyowa Kirin, INC. | $27.38 | 2022 | |
| Krystal Biotech INC | $24.96 | 2023 | Vyjuvek |
| Biofrontera INC. | $14.43 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Macleod listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.